Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders

被引：23

作者：

Dierickx, Daan ^{[1
]}

Delannoy, Andre ^{[2
]}

Saja, Khalid ^{[3
]}

Verhoef, Gregor ^{[1
]}

Provan, Drew ^{[3
]}

机构：

[1] Univ Hosp Leuven, Dept Hematol, B-3000 Louvain, Belgium

[2] Hop Jolimont, Haine St Paul & Clin Univ St Luc, Brussels, Belgium

[3] Barts London Queen Marys Sch Med & Dent, Ctr Hematol, London, England

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2011年 / 86卷 / 03期

关键词：

THROMBOTIC THROMBOCYTOPENIC PURPURA; RED-CELL APLASIA; VERSUS-HOST-DISEASE; CHRONIC LYMPHOCYTIC-LEUKEMIA; TERM-FOLLOW-UP; COLD AGGLUTININ DISEASE; FACTOR-VIII INHIBITORS; LOW-DOSE RITUXIMAB; MINOR HISTOCOMPATIBILITY ANTIGENS; SYSTEMIC-LUPUS-ERYTHEMATOSUS;

D O I：

10.1002/ajh.21939

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Autoimmune hematological disorders encompass a broad group of hematological conditions characterized by the loss of self-tolerance to a variety of antigens. Despite good response to first-line therapy in the majority of patients, relapses are common, necessitating new and safe therapeutic options. The anti-CD20 monoclonal antibody rituximab has led to substantial improvement in the treatment of malignant and immune-mediated disorders involving B cells. Although experience with rituximab in immune-mediated hematological disorders is rarely supported by randomized trials, there is now substantial experience with rituximab suggesting that anti-CD20 therapy is an effective and well-tolerated alternative to immunosuppressive therapy in these disorders. However, caution is needed based on recent reports describing-sometimes severe-rituximab-related complications. Am. J. Hematol. 86:278-291, 2011. (C) 2010 Wiley-Liss, Inc.

引用

页码：278 / 291

页数：14

共 206 条

[31] Rituximab using a thrice weekly dosing schedule in B-Cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity [J].

Byrd, JC ;

Murphy, T ;

Howard, RS ;

Lucas, MS ;

Goodrich, A ;

Park, K ;

Pearson, M ;

Waselenko, JK ;

Ling, G ;

Grever, MR ;

Grillo-Lopez, AJ ;

Rosenberg, J ;

Kunkel, L ;

Flinn, IW .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) :2153-2164

[32] Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease [J].

Canninga-van Dijk, MR ;

van der Straaten, HM ;

Fijnheer, R ;

Sanders, CJ ;

van den Tweel, JG ;

Verdonck, LF .

BLOOD, 2004, 104 (08) :2603-2606

[33]

Caramazza D, 2010, BLOOD TRANSFUS-ITALY, V8, P203, DOI [10.2450/2009-0101-09, 10.2450/2009.0101-09]

[34] Rituximab for allo-SCT-associated thrombotic thrombocytopenic purpura [J].

Carella, A. M. ;

D'Arena, G. ;

Greco, M. M. ;

Nobile, M. ;

Cascavilla, N. .

BONE MARROW TRANSPLANTATION, 2008, 41 (12) :1063-1065

[35] Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project [J].

Carson, Kenneth R. ;

Evens, Andrew M. ;

Richey, Elizabeth A. ;

Habermann, Thomas M. ;

Focosi, Daniele ;

Seymour, John F. ;

Laubach, Jacob ;

Bawn, Susie D. ;

Gordon, Leo I. ;

Winter, Jane N. ;

Furman, Richard R. ;

Vose, Julie M. ;

Zelenetz, Andrew D. ;

Mamtani, Ronac ;

Raisch, Dennis W. ;

Dorshimer, Gary W. ;

Rosen, Steven T. ;

Muro, Kenji ;

Gottardi-Littell, Numa R. ;

Talley, Robert L. ;

Sartor, Oliver ;

Green, David ;

Major, Eugene O. ;

Bennett, Charles L. .

BLOOD, 2009, 113 (20) :4834-4840

[36]

Castillo J, 2009, EXPERT OPIN INV DRUG, V18, P491, DOI [10.1517/13543780902832679 , 10.1517/13543780902832679]

[37] Delayed-onset peripheral blood cytopenia after rituximab: Frequency and risk factor assessment in a consecutive series of 77 treatments [J].

Cattaneo, Chiara ;

Spedini, Pierangelo ;

Casari, Salvatore ;

Re, Alessandro ;

Tucci, Alessandra ;

Borlenghi, Erika ;

Ungari, Marco ;

Ruggeri, Giulia ;

Rossi, Giuseppe .

LEUKEMIA & LYMPHOMA, 2006, 47 (06) :1013-1017

[38] Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab [J].

Chemnitz, J ;

Draube, A ;

Scheid, C ;

Staib, P ;

Schulz, A ;

Diehl, V ;

Söhngen, D .

AMERICAN JOURNAL OF HEMATOLOGY, 2002, 71 (02) :105-108

[39] Long-term follow-up of idiopathic thrombotic thrombocytopenic purpura treated with rituximab [J].

Chemnitz, Jens Marcus ;

Uener, Jens ;

Hallek, Michael ;

Scheid, Christof .

ANNALS OF HEMATOLOGY, 2010, 89 (10) :1029-1033

[40] Autoimmune thrombocytopenia [J].

Chong, BH ;

Ho, SJ .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (08) :1763-1772

← 1 2 3 4 5 6 7 8 9 10 →